Tenascin-X is a novel diagnostic marker of malignant mesothelioma.
Tenascin-X is a novel diagnostic marker of malignant mesothelioma.
复制标题
Tenascin-X是恶性间皮瘤的新型诊断标记。
DOI：
10.1097/pas.0b013e3181b6bde3
复制
发表时间：
2009-11
期刊：
影响因子：
--
通讯作者：
Davidson B
中科院分区：
文献类型：
--
作者：
Yuan Y;Nymoen DA;Stavnes HT;Rosnes AK;Bjørang O;Wu C;Nesland JM;Davidson B
基于基因表达阵列分析，TNXB基因在恶性间皮瘤中比在卵巢/腹膜浆液性癌中表达更高。本研究的目的是在mRNA和蛋白质水平上验证这一发现。采用定量PCR方法检测91例积液（71例卵巢癌、10例乳腺癌、10例恶性间皮瘤）TNXB mRNA的表达。应用免疫组织化学方法研究了Tenascin-X蛋白在183例积液（137例不同来源的癌，37例间皮瘤，9例反应性积液）和178例实性病变（122例卵巢/腹膜癌，56例间皮瘤）中的表达。定量PCR分析显示，与卵巢癌和乳腺癌相比，间皮瘤中TNXB mRNA水平显著升高（p<0.001）。免疫组化结果显示，tenascin-X蛋白在恶性间皮瘤中的表达明显高于积液中的转移性癌（34/37 vs 31/137阳性病例，敏感性= 92%，特异性= 77%,p<0.001）。反应性间皮细胞局灶性表达或不表达tenascin-X。41/56例间皮瘤活检标本检出Tenascin-X蛋白，122例卵巢癌均未检出Tenascin-X蛋白（敏感性= 73%，特异性= 100%,p<0.001）。我们的数据表明，tenascin-X可能是恶性间皮瘤在涉及浆膜腔的癌症鉴别诊断中的一个新的诊断标志物，特别是在该肿瘤与卵巢/腹膜浆膜癌的鉴别诊断中。
TNXB was previously identified as a gene that is more highly expressed in malignant mesothelioma compared to ovarian/peritoneal serous carcinoma based on gene expression array analysis. The objective of the present study was to validate this finding at the mRNA and protein level. Effusions (n=91; 71 ovarian carcinomas, 10 breast carcinomas, 10 malignant mesotheliomas) were assayed for TNXB mRNA expression using quantitative PCR. Tenascin-X protein expression was studied in 183 effusions (137 carcinomas of different origin, 37 mesotheliomas, 9 reactive effusions) and 178 solid lesions (122 ovarian/ peritoneal carcinomas, 56 mesotheliomas) using immunohistochemistry. Quantitative PCR analysis showed significantly higher TNXB mRNA level in mesotheliomas compared to ovarian and breast carcinomas (p<0.001). By immunohistochemistry, tenascin-X protein expression was significantly higher in malignant mesothelioma compared to metastatic carcinoma in effusions (34/37 vs. 31/137 positive cases; sensitivity = 92%, specificity = 77%; p<0.001). Reactive mesothelial cells had focal or no tenascin-X expression. Tenascin-X protein was detected 41/56 mesothelioma biopsy specimens, and was uniformly absent from all 122 ovarian carcinomas (sensitivity = 73%, specificity = 100%; p<0.001). Our data suggest that tenascin-X may be a new diagnostic marker of malignant mesothelioma in the differential diagnosis of cancers involving the serosal cavities, particularly in the differential diagnosis between this tumor and ovarian/peritoneal serous carcinoma.